利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.011 秒)

    ASSESSMENT OF RISK OF HYPERTENSION AND METHODS BASED THEREON
    1.
    发明公开
    ASSESSMENT OF RISK OF HYPERTENSION AND METHODS BASED THEREON 审中-公开
    高血压客观评定和基于事实的过程中的风险

    公开(公告)号：EP2926132A1

    公开(公告)日：2015-10-07

    申请号：EP13811805.4

    申请日：2013-11-26

    申请人： Westfälische Wilhelms-Universität Münster

    发明人： OBERLEITHNER, Hans

    IPC分类号： G01N33/48

    CPC分类号： G01N13/04 ,  G01N33/49 ,  G01N33/6893 ,  G01N2013/003 ,  G01N2800/322

    摘要： Provided is a method of analysing whether the blood pressure of a subject is sensitive to sodium intake and/or of assessing the susceptibility of a subject to develop hypertension. In the method erythrocytes of the subject are suspended in two sodium chloride solutions of about physiological osmolality. The sodium chloride concentration of one of the two solutions is at least about 25 mM lower than in the other solution. After allowing the suspended erythrocytes in the two sodium chloride solutions to settle for a period of time sufficient to allow the formation of a supernatant the difference in height of the supernatant between the two sodium chloride solutions is detected. An increased difference in height of the supematants, relative to a threshold value, indicates that the subject's blood pressure is sensitive to sodium intake and/or that the subject is susceptible to develop hypertension.

    A NEW METHOD FOR DIAGNOSING HYPERTENSION AS WELL AS CARDIOMYOPATHIES
    3.
    发明公开
    A NEW METHOD FOR DIAGNOSING HYPERTENSION AS WELL AS CARDIOMYOPATHIES 有权
    VERFAHREN ZUR DIAGNOSE VON HYPERTONIE SOWIE KARDIOMYOPATHIEN

    公开(公告)号：EP2625202A1

    公开(公告)日：2013-08-14

    申请号：EP11766928.3

    申请日：2011-09-22

    申请人： CellTrend GmbH

    发明人： HEIDECKE, Harald ,  SCHULZE-FORSTER, Kai

    IPC分类号： C07K16/28 ,  G01N33/53

    CPC分类号： G01N33/6887 ,  C07K16/28 ,  C07K16/2869 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/32 ,  G01N2800/322

    摘要： A method for diagnosis and/or prediction of hypertension and/or cardiovascular end-organ damage is disclosed. The method disclosed comprises the determination of the presence of soluble pro-renin receptor in samples derived from a subject. Furthermore, the use of anti- sPRR antibodies in diagnosis and/or prediction of cardiovascular end-organ damage is encompassed.

    摘要翻译： 公开了用于诊断和/或预测高血压和/或心血管终末器官损伤的方法。 所公开的方法包括来自受试者的样品中可溶性前肾素受体的存在的测定。 此外，还包括在诊断和/或预测心血管终末器官损伤中使用抗sPRR抗体。

    Biomakers for the diagnosis, prognosis, assessment and therapy stratification syncope
    6.
    发明公开
    Biomakers for the diagnosis, prognosis, assessment and therapy stratification syncope 审中-公开
    生物标记zur诊断，Vorhersage，Beurteilung und Therapiesynkopenschichtung

    公开(公告)号：EP2657707A1

    公开(公告)日：2013-10-30

    申请号：EP12002935.0

    申请日：2012-04-26

    申请人： B.R.A.H.M.S GmbH

    发明人： Struck, Joachim ,  Melander, Olle ,  Fedorowski, Artur

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2800/322 ,  G01N2800/52

    摘要： The present invention relates to a method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising:
    determining the level of at least one biomarker selected from the group consisting of proADM, proANP, proBNP, proAVP, proET-1 and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient, correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.

    摘要翻译： 本发明涉及一种用于诊断和/或预后和/或评估和/或治疗患者晕厥的治疗方法，所述方法包括：确定至少一种选自以下的生物标志物的水平：proADM，proANP， proBNP，proAVP，proET-1和PCT或其至少12个氨基酸的片段，在所述患者的体液样品中，将所述至少一种生物标志物或其片段的水平与诊断和/或预后相关联，以及 /或评估和/或治疗晕厥分层。

    BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS, ASSESSMENT AND THERAPY STRATIFICATION OF SYNCOPE
    9.
    发明公开
    BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS, ASSESSMENT AND THERAPY STRATIFICATION OF SYNCOPE 有权
    生物识别器ZUR THERAPEUTISCHEN SCHICHTUNG VON SYNKOPEN

    公开(公告)号：EP2841949A1

    公开(公告)日：2015-03-04

    申请号：EP13717432.2

    申请日：2013-04-12

    申请人： B.R.A.H.M.S GmbH

    发明人： STRUCK, Joachim ,  MELANDER, Olle ,  FEDOROWSKI, Artur

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2800/322 ,  G01N2800/52

    摘要： The present invention relates to a method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising: determining the level of at least one biomarker selected from the group consisting of proET-1, pro ADM, proANP, proBNP, proAVP and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient, correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.

    摘要翻译： 本发明涉及一种用于诊断和/或预后和/或评估和/或治疗患者晕厥的治疗方法，所述方法包括：确定至少一种选自以下的生物标志物的水平：proADM，proANP， proBNP，proAVP，proET-1和PCT或其至少12个氨基酸的片段，在所述患者的体液样品中，将所述至少一种生物标志物或其片段的水平与诊断和/或预后相关联，以及 /或评估和/或治疗晕厥分层。